Skip to content
University of Colorado DenverCU DenverUniversity of Colorado Anschutz Medical CampusCU Anschutz
  • Webmail
  • UCD Access
  • Canvas
  • Quick Links
 
 

Tools & Resources

  • Campus Directory
  • A-Z Index
  • Human Resources
  • University Policies
  • Auraria Library
  • Strauss Health Sciences Library

Schools & Colleges

CU Denver

  • College of Architecture and Planning
  • College of Arts & Media
  • Business School
  • School of Education & Human Development
  • College of Engineering, Design and Computing
  • College of Liberal Arts and Sciences
  • School of Public Affairs

CU Anschutz Medical Campus

  • School of Dental Medicine
  • Graduate School
  • School of Medicine
  • College of Nursing
  • Skaggs School of Pharmacy and Pharmaceutical Sciences
  • Colorado School of Public Health

CU Campuses

  • CU Anschutz Medical Campus
  • CU Boulder
  • CU Colorado Springs
  • CU Denver
  • CU Online
  • CU System

SPARK | REACH Colorado

  • Home
  • SPARK Awards
    • What We Fund
    • Application Process
    • Our Funding Sources
    • FAQs
    • Submit an Application
  • Who We Are
    • SPARK Fellows
    • External Review Board
    • SPARK Team
  • Events
    • SPARK Upcoming Events
    • SPARK Past Events
  • Get Involved
  • Resources
    • SPARK Documents
    • Applicant Support: Bootcamp Sessions
  • Contact Us
University Quick Links

Meet our SPARK Fellows

Sujatha Venkataraman, PhD

Email Address:SUJATHA.VENKATARAMAN@CUANSCHUTZ.EDU

  • Bio

Novel Therapeutic Antibody against a Fatal Brain Tumor in Children

This project aims to address the urgent need for effective treatments for Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive brain tumor in children with a 0% 5-year survival rate since 1950. Current therapies like radiation and chemotherapy have limited success, and surgical resection is not feasible due to the tumor's location in a critical brain region. The researchers have identified CD99 as a promising target in DIPG and developed a novel monoclonal antibody (10D1 mAb) that showed superior efficacy in preclinical models compared to existing antibodies. They plan to engineer a fully humanized version of the antibody (HuCD99-IgG4) and conduct comprehensive preclinical studies to determine its safety and effectiveness in patient-derived xenograft models. The team's expertise in brain tumor biology, antibody development, preclinical testing, and clinical trials positions them to advance HuCD99-IgG4 as a potential treatment for DIPG patients. Collaborator: Rajeev Vibhakar, MD, PhD, MPH/MSPH

Learn more about Dr. Venkataraman

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


303-724-6653

Facebook Twitter LinkedIn
Additional Resources
  • CU Innovations
  • SPARK@Stanford
  • Other Funding Opportunities
  • Startup Toolbox
  • Contact Us
  • Website Feedback
  • CU System
  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Accreditation
  • Employment
  • Give Now
 

© 2023 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.

CMS Login

Webmail

UCD Access

Canvas

Opens in a new window Opens document in a new window